Meaningful biomarkers in myeloproliferative neoplasms and Q&A

During the MPN Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss meaningful biomarkers in myeloproliferative neoplasms (MPN). Benjamin Rolles delivered a presentation on potential biomarkers in MPN and the impact this may have on clinical practice and management strategies.

Benjamin Rolles opens by discussing the biomarkers associated with driving MPN, going on to highlight the need to better understand clonal hematopoiesis, particularly why certain healthy individuals within the population can harbor MPN driver gene mutations but not develop MPNs while others do. Rolles also covers high-risk constellations in MPN as well as biomarkers for disease monitoring. Rolles concluded that there is still a significant need for new and improved biomarkers in MPN in order to optimize treatment monitoring, treatment selection, and predicting adverse events.

Q&A

Following their presentation, Rolles chaired a Q&A session featuring steering committee members Alessandro Vannucchi, Laura Michaelis, Haifa Kathrin Al-Ali, Tiziano Barbui, Steffen Koschmieder, and Chloe James. Discussions include how to assess allele burden frequency in the clinic, the importance of this in diagnosis, and when to measure allelic burden. This Q&A session closes with a discussion on the management strategies for patients with a consistent increase of variant allele frequency.